

## Note

### Synthesis and antibacterial activity of nitro-furylvinylquinazolinones

B Shivarama Holla<sup>\*a</sup>, M T Padmaja<sup>a</sup>, M K Shivananda<sup>a</sup>  
& P M Akbarali<sup>b</sup>

<sup>a</sup>Department of Chemistry, Mangalore University,  
Mangalagangothri 574 199, India


<sup>b</sup>Plama Laboratories Ltd, 120A/B, Industrial Area,  
Baikampady, New Mangalore 575 011, India

Received 14 October 1996; accepted (revised) 14 July 1997

The reaction of 3-aryl-2-methyl-quinazolin-4-ones **1** with acidified nitrofurfuraldehyde diacetate **2** in the presence of piperidine affords 3-aryl-2-[(5-nitro-2-furyl)vinyl]quinazolin-4-ones **3** in 50-80% yield. These compounds have been characterized by nitrogen analysis, and IR, <sup>1</sup>H NMR and mass spectral data. The newly synthesized compounds have been screened for their antibacterial activities.

Quinazolinone derivatives exhibit a wide range of antiparkinson<sup>1</sup>, antibacterial<sup>1</sup>, anthelmintic<sup>2</sup>, CNS depressant<sup>3</sup>, antitubercular<sup>4</sup>, analgesic<sup>5</sup>, antiinflammatory<sup>6</sup>, hypoglycemic<sup>7</sup>, non-steroidal<sup>8</sup> and fungicidal activities. The 4(3*H*)-quinazolinone<sup>9</sup> moiety constitutes an important structural feature in several useful sedatives, hypnotic and anticonvulsant drugs such as Methaqualone and Mecloqualone. Further, nitrofurans are being used as potential chemotherapeutic agents<sup>10-11</sup>. In view of these observations and in continuation of our studies on chemotherapeutically important nitrofurans<sup>12-14</sup>, it was thought of interest to synthesize novel 3-aryl-2-[(5-nitro-2-furyl)vinyl]-quinazolin-4-ones **3**.

For the present work, various anilines were condensed with 2-methyl-3,1-benzoxazin-4-one in the presence of phosphorus oxychloride employing toluene as solvent. Such condensations afforded 3-aryl-2-methyl-quinazolin-4-ones **1** in 60-70% yield. The required 2-methyl-3,1-benzoxazin-4-one was prepared by the cyclization of anthranilic acid with acetic anhydride. Quinazolinones **1** were characterized by their melting points and reference to literature<sup>15</sup>. 3-Aryl-2-methylquinazolin-4-ones **1** were then condensed with acidified nitrofurfuraldehyde diacetate **2** in the presence of a base such as



Scheme I

piperidine to yield **3** (Scheme I). Nitrofurfuraldehyde diacetate **2**, required for this reaction, was obtained by the literature method<sup>16</sup>. Characterization and spectral data of compounds **3** are given in Table I.

**Antibacterial Activity.** All the newly synthesized compounds were screened for their antibacterial activity against *Bacillus subtilis*, *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. All of them showed antibacterial activity at 5 µg/mL to a lesser degree than that of Furacin, a standard drug used for comparison.

### Experimental Section

**General.** Melting points were determined in open capillaries and are uncorrected. IR spectra were recorded on a Shimadzu FT-IR 157 infrared spectrophotometer, <sup>1</sup>H NMR spectra in DMSO-*d*<sub>6</sub> on a 90 MHz Perkin-Elmer R-32 instrument using TMS as internal reference (chemical shifts in δ, ppm) and mass spectra on a Jeol JMS-D 300 mass spectrometer.

Table I—Characterization data of 3-aryl-2-[(5-nitro-2-furyl)vinyl]quinazolin-4-ones 3\*

Compd	R	Yield (%)	m.p. °C	Nature of the compound	Mol. Formula
3a	H	80	254	Orange yellow crystals	C <sub>20</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub>
3b	<i>p</i> -Bromo <sup>†</sup>	81	229	Yellow crystals	C <sub>20</sub> H <sub>12</sub> BrN <sub>3</sub> O <sub>3</sub>
3c	<i>p</i> -Methyl	78	213	Orange crystals	C <sub>21</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub>
3d	<i>m</i> -Chloro	57	231	Yellowish shining needles	C <sub>20</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>3</sub>
3e	3-Chloro-4-fluoro <sup>‡</sup>	81	196	Yellow crystals	C <sub>20</sub> H <sub>11</sub> ClFN <sub>3</sub> O <sub>3</sub>
3f	<i>o</i> -Methoxy	51	191	Light yellow crystals	C <sub>21</sub> H <sub>15</sub> N <sub>3</sub> O <sub>4</sub>
3g	<i>m</i> -Methyl	68	197	Yellow crystals	C <sub>21</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub>
3h	<i>p</i> -Nitro	50	242	Brownish orange crystals	C <sub>20</sub> H <sub>12</sub> N <sub>4</sub> O <sub>5</sub>
3i	2,5-Dichloro	53	226	Light yellow crystals	C <sub>20</sub> H <sub>11</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>3</sub>

\*Satisfactory elemental analyses ( $\pm 0.3\%$ ) were obtained.

<sup>†</sup>IR: 1675 (C=O), 1600 (C=C), 1550 and 1340 cm<sup>-1</sup> (NO<sub>2</sub> *asym* and *sym*)

<sup>‡</sup>IR: 1681 (C=O), 1600 (C=C), 1545 and 1340 cm<sup>-1</sup> (NO<sub>2</sub> *asym* and *sym*)

**3-Aryl-2-[(5-nitro-2-furyl)vinyl] quinazolin-4-ones 3: General procedure.** An equimolecular mixture of suitably substituted quinazolinone 1 (0.01 mole) and 5-nitro-2-furfuraldehyde diacetate (2.43 g, 0.01 mole) in absolute ethanol (20 mL) was treated first with conc. sulphuric acid (0.5 mL) followed by the addition of piperidine (10 mL). The mixture was heated under reflux for 1-2 hr. On cooling the reaction mixture, the resultant product was filtered, washed and recrystallized from dimethylformamide. The characterization data of compounds 3 are given in Table I.

As a representative case the spectral data of 3c are given below: IR: 1680 (C=O), 1600 (C=C), 1540 and 1340 cm<sup>-1</sup> (NO<sub>2</sub> *asym* and *sym*). <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>): 3c  $\delta$  2.5 (s, 3H, *p*-tolyl protons), 6.5-6.7 (d, 2H, vinyl protons), 7.1-7.4 (m, 8H, aromatic protons), 7.7-7.9 (d, 2H, furan protons). MS: *m/z* 359 (M<sup>+</sup>), 313 (M-NO<sub>2</sub>).

#### Acknowledgement

The authors are thankful to Head, RSIC, CDRI, Lucknow and Director, SIF, IISc., Bangalore for providing nitrogen analyses, mass and <sup>1</sup>H NMR spectral data. They are also thankful to Prof. M V Ramana, N.G.S.M. College of Pharmacy, Deralakatte for his help in carrying out the antibacterial activities of the compounds reported herein. Two of them (M K S and M T P) are grateful to CSIR,

New Delhi and Plasma Laboratories Ltd., respectively for research fellowships.

#### References

- 1 Srivastava V K, Singh S, Gulati A & Shanker K, *Indian J Chem*, 26B, 1987, 652.
- 2 Gupta D P, Ahmad S, Kumar A & Shanker K, *Indian J Chem*, 27B, 1988, 1060.
- 3 Chaurasia M R & Sharma A K, *J Indian Chem Soc*, 52, 1985, 308.
- 4 Joshi V & Chaudhari R P, *Indian J Chem*, 26B, 1987, 602.
- 5 Ram V J, Srimal R C, Kushwaha D S & Mishra L J, *J Prakt Chem*, 332, 1990, 629.
- 6 Kumar A, Singh S, Saxena A K & Shanker K, *Indian J Chem*, 27B, 1988, 443.
- 7 Husain M I & Jamali M R, *Indian J Chem*, 27B, 1988, 43.
- 8 Ram V J & Verma M, *Indian J Chem*, 30B, 1991, 1119.
- 9 Abdel-Alim M, Abdel Alim, Abdel-Nasser, AEL-Shorbaji, Hosny A H, El-Sharief Mahmoud, AEL-Gendy & Monir Amin, *Indian J Chem*, 33B, 1994, 260.
- 10 Dodd M C & Stillman W B, *J Pharmacol Exp Therap*, 82, 1944, 11.
- 11 Nardi D, Massarani E, Tajana A, Degen L & Magistretti M J, *J Med Chem*, 10, 1967, 530.
- 12 Holla B S, Kalluraya B, Sridhar K R, Drake E, Thomas L M, Bhandary K K & Levine M J, *Eur J Med Chem*, 29, 1994, 301.
- 13 Holla B S, Udupa K V & Sridhar K R, *Bull Chem Soc Japan*, 65, 1988, 524.
- 14 Holla B S & Kalluraya B, *Indian J Chem*, 27B, 1988, 683.
- 15 Klosa J, *J Prakt Chem*, 14, 1961, 84; *Chem Abstr*, 56, 1962, 2449.
- 16 Gillman H & Wright G F, *J Am Chem Soc*, 52, 1936, 2553.